FDA approves generic liraglutide injection from Orbicular and Cipla
A newly approved generic liraglutide injection adds another FDA-cleared supplier of a GLP-1 drug, but its price, launch timing and coverage have not been disclosed.
The FDA approved a generic form of the injectable GLP-1 drug liraglutide on January 14, 2026, according to the agency's drug approval database [1]. The product is a 6 mg/mL solution given by subcutaneous injection, and the approval record carries two companies' labels [1].
The application is ANDA217590, filed by Orbicular and reviewed under standard priority [1]. The record lists the submission as approved with a status date of January 14, 2026 [1]. Two manufacturer names appear in the entry: Orbicular Pharmaceutical Technologies Private Limited and Cipla USA Inc. [1].
The approved product is listed as liraglutide 18 mg/3 mL (6 mg/mL), a prescription solution for subcutaneous use [1]. Its national drug codes are 81607-018 for the Orbicular label and 69097-920 for the Cipla USA label [1]. The package codes listed are 81607-018-01, 81607-018-02, 69097-920-67 and 69097-920-68 [1].
The record gives the product a therapeutic equivalence code of AP1 and describes it as an abbreviated new drug application, the FDA pathway used for generic versions of drugs that are already approved [1]. The active ingredient is listed as liraglutide, and the drug class as GLP-1 receptor agonist [1]. Liraglutide is a separate molecule from semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus, and from tirzepatide, the ingredient in Mounjaro and Zepbound [1].
The entry marks the reference drug and reference standard fields as "No," meaning the product is not itself listed as a brand-name reference product in the database [1]. The record does not name the brand-name liraglutide product the generic was compared with, and it does not include any pricing, launch or supply details [1].
Why it matters for patients
Liraglutide is an injectable GLP-1 receptor agonist, a class used for diabetes and weight management, and an additional FDA-approved version can affect which manufacturer's product a pharmacy dispenses and what an insurer pays [1]. The approval record itself contains none of that information: it lists no price, no launch date, and no Medicare or commercial coverage terms for either label [1]. Whether the product is already in pharmacies, and what it costs, has not been reported [1].
People who fill a liraglutide prescription may eventually see a different company's name on the packaging, since the same application covers products marketed by Orbicular and by Cipla USA [1]. Questions about a specific prescription, including whether one version can be swapped for another at the pharmacy, are handled by prescribers and pharmacists; the approval record does not address substitution [1].
What happens next
The January 14, 2026 approval is the only dated milestone in the record [1]. Launch timing, list price, and insurance coverage for the Orbicular and Cipla USA products have not been disclosed [1]. No information on manufacturing volume or supply has been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.